Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-02-06
2007-02-06
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S469000, C548S470000, C548S472000, C548S478000, C514S415000, C514S416000
Reexamination Certificate
active
10748085
ABSTRACT:
The invention encompasses novel compounds, pharmaceutically acceptable salts, hydrates, solvates, clathrates, enantiomers, diastereomers, racemates, or mixtures of stereoisomers thereof, pharmaceutical compositions of these compounds, and methods of using these compounds and compositions in mammals for treatment or prevention of diseases associated with PDE4.
REFERENCES:
patent: 6200987 (2001-03-01), Muller
patent: 6214857 (2001-04-01), Muller et al.
patent: 6326388 (2001-12-01), Man et al.
patent: 6911464 (2005-06-01), Man et al.
patent: 7034052 (2006-04-01), Man et al.
patent: 298 389 (1983-10-01), None
patent: WO 97/23457 (1997-07-01), None
patent: WO 01/34603 (2001-05-01), None
patent: WO 01/34606 (2001-05-01), None
patent: WO 01/90076 (2001-11-01), None
patent: WO 02/16305 (2002-02-01), None
Baughman et al., 1990, “Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis,” J. Lab. Clin. Med. 115(1): 36-42.
Beavo et al., 1990, “Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors,” Trends Pharmacol. Sci. 11(4): 150-155.
Beckett et al., 1996, Drug Discovery Today 1:16-26.
Berge et al., 1977, “Pharmaceutical salts,” J. Pharm. Sci. 66(1): 1-19.
Bertolini et al., 1986, “Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors,” Nature 319(6053): 516-518.
Bissonnette et al., 1989, “Pulmonary inflammation and fibrosis in a murine model of asbestosis and silicosis. Possible role of tumor necrosis factor,” Inflammation 13(3): 329-339.
Clouse et al., 1989, “Monokine regulation of human immunodeficiency virus-1 expression in a chromically infected human T cell clone,” J. Immunol. 142(2): 431-438.
Dezube et al., 1990, “Pentoxifylline and wellbeing in patients with cancer,” Lancet 335(8690):662.
Duh et al., 1989, “Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat,” Proc. Natl. Acad. Sci. USA 86(15): 5974-5978.
Elliott et al., 1995, “TNF alpha blockade in rheumatoid arthritis: rationale, clinical outcomes and mechanisms of action,” Int. J. Immunopharmacol. 17(2): 141-145.
Ferrai-Baliviera et al., 1989, “Tumor necrosis factor induces adult respiratory distress syndrome in rats,” Arch. Surg. 124(12): 1400-1405.
Folks et al., 1989, “Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone,” Proc. Natl. Acad. Sci. USA 86(7): 2365-2368.
Grau et al., 1989, “Tumor necrosis factor and disease severity in children with falciparum malaria,” N. Engl. J. Med. 320(24):1586-91.
Grewe et al., 1982, “Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness,” J. Allergy Clin. Immunol. 70(6): 452-457.
Guay et al., 2002, “Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor,” Bioorg. Med. Chem. Lett. 12(11): 1457-1461.
Hanifin et al., 1996, “Type 4 Phosphodiesterase Inhibitors Have Clinical and in vitro Anti-inflammatory Effects in Atopic Dermatitis,” J. of Investigative Dermatology 107(1):51-56.
Hatzelmann et al., 2001, “Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro,” J. Pharmacol. Exp. Ther. 297(1):267-279.
Hinshaw et al., 1990, “Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha),” Circ. Shock 30(3):279-292.
Holler et al., 1990, “Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation,” Blood 75(4): 1011-1016.
Houslay et al., 1998, “The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions,” Adv. Pharmacol. 44:225-342.
Huang et al., 2001, “The Next Generation of PDE4 inhibitors,” Curr. Opin. Chem. Biol. 5:432-438.
Johnson et al., 1989, “Tumors producing human tumor necrosis factor induced hypercalcemia and osteoclastic bone resorption in nude mice,” Endocrinology 124(3):1424-1427.
List et al., 1990, “The myelodysplastic syndromes: biology and implications for management,” J. Clin. Oncol. 8(8):1424-1441.
Lowe et al., 1992, Drugs of the Future 17(9):799-807.
Millar et al., 1989, “Tumour necrosis factor in bronchopulmonary secretions of patients with adult respiratory distress syndrome,” Lancet 2(8665):712-714.
Monte et al., 1990, “Productive human immunodeficiency virus-1 infection of megakaryocytic cells is enhanced by tumor necrosis factor-alpha,” Blood 79(10): 2670-2679.
Piguet et al., 1990, “Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis,” Nature 344(6263):245-247.
Poli et al., 1990, “Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression,” Proc. Natl. Acad. Sci. USA 87(2): 782-785.
Poli et al., 1992, “The effect of cytokines and pharmacologic agents on chronic HIV infection,” AIDS Res. Hum. Retroviruses 8(2):191-197.
Rice et al., 1989, “An inducible endothelial cell surface glycoprotein mediates melanoma adhesion,” Science 246(4935):1303-1306.
Shealy et al., 1968, “Synthesis of D- and L-thalidomide and related studies,” J. Pharm. Sci. 57(5):757-764.
Shealy et al., 1965, “D- and L-thalidomide,” Chem. Ind. 24:1030-1031.
Tierney et al., ed., 1998, Curr. Med. Diag. Treat. 37th ed., 499.
Tracey et al., 1987, “Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia,” Nature 330(6149):662-664.
Verghese et al., 1995, “Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors,” J. Pharmacol. Exp. Ther. 272(3): 1313-1320.
Van Dullemen et al., 1995, “Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2),” Gastroenterology 109(1):129-135.
Man Hon-Wah
Muller George W.
Zhang Weihong
Celgene Corporation
Jones Day
Shameem Golam M. M.
LandOfFree
Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3829365